DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Wils P, Bouhnik Y, Michetti P. et al.
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohnʼs Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Clin Gastroenterol Hepatol 2016;
14: 242-250 e241–242
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.